According to the FLAURA trial, osimertinib showed efficacy superior to that of standard EGFR‐TKIs in the first‐line treatment of EGFR mutation‐positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events.22 However, evidence of the effectiveness of osimertinib in SqCC with EGFR T790M mutation is limited. Here, EGFR is linked to non-small cell lung carcinoma.